280
Participants
Start Date
April 15, 2025
Primary Completion Date
March 27, 2029
Study Completion Date
March 27, 2029
Raludotatug Deruxtecan
IV infusion on Day 1 of every 3-week cycle.
Carboplatin
IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles.
Paclitaxel
IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles.
Bevacizumab
IV infusion on Day 1 of every 3-week cycle.
Rescue Medication
Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol.
Pembrolizumab
IV infusion on Day 1 of every 3-week cycle for a maximum of 35 cycles.
RECRUITING
Memorial Sloan Kettering Cancer Center ( Site 0003), New York
RECRUITING
University of Virginia Health System ( Site 0011), Charlottesville
RECRUITING
Clinica Universidad de Navarra ( Site 0301), Madrid
RECRUITING
Hospital Universitario Fundación Jiménez Díaz-START Madrid-FJD ( Site 0303), Madrid
RECRUITING
Hospital Universitario 12 de Octubre ( Site 0304), Madrid
RECRUITING
The University of Louisville, James Graham Brown Cancer Center ( Site 0009), Louisville
RECRUITING
Houston Methodist Hospital ( Site 0010), Houston
RECRUITING
START Mountain Region ( Site 0008), West Valley City
RECRUITING
Rambam Health Care Campus ( Site 0202), Haifa
RECRUITING
Sheba Medical Center ( Site 0200), Ramat Gan
RECRUITING
Shaare Zedek Medical Center ( Site 0201), Jerusalem
RECRUITING
Institut Català d'Oncologia - L'Hospitalet ( Site 0302), L'Hospitalet de Llobregat
RECRUITING
Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 0300), Barcelona
RECRUITING
Royal Marsden Hospital ( Site 0402), Fulham
RECRUITING
The Royal Marsden NHS Foundation Trust. ( Site 0403), Sutton
Collaborators (1)
Daiichi Sankyo
INDUSTRY
Merck Sharp & Dohme LLC
INDUSTRY